Top-line interim data from Madrigal Pharmaceuticals Inc.'s Phase II study of its MGL-3196 in non-alcoholic steatohepatitis (NASH) show a 36% median reduction in liver fat after 12 weeks of treatment, leading investors and market analysts to think about bull-case scenarios for the selective thyroid hormone receptor (THR) beta agonist.
The Philadelphia-area biotech unveiled the 12-week data Dec. 6 and said it expected to have final top-line data by late April 2018, potentially putting it on pace to initiate a...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?